Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1652-1653

  Sekimizu, Masahiro ^a   Yamashita, Yuka ^a   Ueki, Hideaki ^a   Akita, Nobuhiro ^a   Hattori, Hiroyoshi ^a   Maeda, Naoko ^a   Horibe, Keizo ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HLA DR ANTIGEN; IMATINIB; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; NILOTINIB; PREDNISOLONE; VINCRISTINE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CASE REPORT; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE 46,XY; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT RESPONSE; X CHROMOSOME ABERRATION; DRUG RESISTANCE; GENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; DASATINIB; DRUG RESISTANCE, NEOPLASM; HUMANS; IMATINIB MESYLATE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84903442808     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.842984     Document Type: Letter

References (14)

1. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hckand Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but notchronic myeloid leukemia. Nat Genet 2004 ; 36 : 453-461.
2. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses theblood-brain barrier and is an effi cient therapy for central nervoussystem Philadelphia chromosome-positive leukemia. Blood 2008; 112:1005-1012.
3. Manabe A, Kawasaki H, Chin M, et al. Abrief use of imatinibimmediately before hematopoietic stem cell transplantation(HSCT) in children with Philadelphia chromosome-positive acutelymphoblastic leukemia (PhALL). Results of the Japanese PediatricLeukemia/Lymphoma Study Group (JPLSG) study PhALL04. Blood2011; 118(Suppl. 1): Abstract 2554.
4. Thomas D A, Faderl S, Cortes J, et al. Treatment of Philadelphiachromosome-positive acute lymphocytic leukemia with hyper-CVADand imatinib mesylate. Blood 2004 ; 103 : 4396-4407.
5. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-freesurvival with imatinib in Philadelphia chromosome-positive acutelymphoblastic leukemia: a children ' s oncology group study. J Clin Oncol 2009 ; 27 : 5175-5181.
6. Ono T, Miyawaki S, Kimura F, et al. BCR-ABL1 mutations inpatients with imatinib-resistant Philadelphia chromosomepositiveleukemia by use of the PCR-Invader assay. Leuk Res 2011 ; 35 :598-603.
7. Hochhaus A, La R osé e P, Müller M C, et al. Impact of BCR-ABLmutations on patients with chronic myeloid leukemia. Cell Cycle2011 ; 10 : 250-260.
8. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: anupdate of concepts and management recommendations of EuropeanLeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-6051.
9. Branford S, Melo JV, Hughes TP. Selecting optimal secondlinetyrosine kinase inhibitor therapy for chronic myeloid leukemiapatients after imatinib failure: does the BCR-ABL mutation statusreally matter? Blood 2009 ; 114 : 5426-5435.
10. Castillo E, Al-Rajabi R, Pandya D M, et al. Apilot study ofthe combination of nilotinib and hyper-CVAD for Philadelphiachromosome positive acute lymphocytic leukemia and lymphoidblast crisis chronic myelogenous leukemia. Blood 2010 ; 116 : 885-886.
11. Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II studyof nilotinib in patients with relapsed or refractory Philadelphiachromosome-positive acute lymphoblastic leukemia. Leukemia 2013 ;27 : 1411-1413.
12. Jabbour E, Kantarjian HM, Jones D, et al. Characteristics andoutcome of chronic myeloid leukemia patients with F317L BCR-ABLkinase domain mutation after therapy with tyrosine kinase inhibitors.Blood 2008 ; 112 : 4839-4842.
13. Potenza L, Volzone F, Riva G, et al. Interferon-alpha may restoresensitivity to tyrosine-kinase inhibitors in Philadelphia chromosomepositive acute lymphoblastic leukaemia with F317L mutation. Br J Haematol 2009 ; 146 : 227-230.
14. Chang BH, Willis SG, Stork L, et al. Imatinib resistant BCRABL1mutations at relapse in children with Ph ALL: A Children ' sOncology Group (COG) study. Br J Haematol 2012 ; 157 : 507-510.